Achillion shares should be bought ahead of data, says Piper Jaffray Piper Jaffray recommends buying Achillion's stock ahead of data from its ACH-3102 + ribavarin for HCV in April. The firm was encouraged by interim data on ACH-3102 and continues to see the company as a likely takeout candidate. It maintains an Overweight rating on the shares.
Achillion March calls active on renewed takeover chatter Achillion March 14 and April 15 calls are active on total call volume of 1,600 contracts (100 puts) on renewed takeover chatter. February weekly call option implied volatility is at 82, March and April is at 79, June is at 81; compared to its 10-week average of 81 according to Track Data. Active call volume suggests traders taking positions for large near term price movement.